NPPB and cancer: Our study demonstrated that LV GLS may be used as an early diagnostic marker of anthracycline-induced subclinical LV cardiotoxicity together with increased levels of NT-ProBNP, enabling early start of CPT in those patients, which prevented further worsening of LVEF without interrupting the cancer treatment.